217 related articles for article (PubMed ID: 26823337)
1. Vaccine-Induced Immunogenicity and Protection Against Pneumocystis Pneumonia in a Nonhuman Primate Model of HIV and Pneumocystis Coinfection.
Kling HM; Norris KA
J Infect Dis; 2016 May; 213(10):1586-95. PubMed ID: 26823337
[TBL] [Abstract][Full Text] [Related]
2. Immunization with
Cobos Jiménez V; Rabacal W; Rayens E; Norris KA
Hum Vaccin Immunother; 2019; 15(9):2075-2080. PubMed ID: 31348719
[TBL] [Abstract][Full Text] [Related]
3. A therapeutic vaccine strategy to prevent
Rabacal W; Schweitzer F; Kling HM; Buzzelli L; Rayens E; Norris KA
Front Immunol; 2022; 13():1036658. PubMed ID: 36561749
[TBL] [Abstract][Full Text] [Related]
4. Relationship of Pneumocystis jiroveci humoral immunity to prevention of colonization and chronic obstructive pulmonary disease in a primate model of HIV infection.
Kling HM; Shipley TW; Patil SP; Kristoff J; Bryan M; Montelaro RC; Morris A; Norris KA
Infect Immun; 2010 Oct; 78(10):4320-30. PubMed ID: 20660609
[TBL] [Abstract][Full Text] [Related]
5. Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia.
Gingo MR; Lucht L; Daly KR; Djawe K; Palella FJ; Abraham AG; Bream JH; Witt MD; Kingsley LA; Norris KA; Walzer PD; Morris A
J Acquir Immune Defic Syndr; 2011 Jul; 57(3):190-6. PubMed ID: 21372726
[TBL] [Abstract][Full Text] [Related]
6. Pneumocystis infection and the pathogenesis of chronic obstructive pulmonary disease.
Norris KA; Morris A
Immunol Res; 2011 Aug; 50(2-3):175-80. PubMed ID: 21717077
[TBL] [Abstract][Full Text] [Related]
7. Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection.
Walzer PD; Djawe K; Levin L; Daly KR; Koch J; Kingsley L; Witt M; Golub ET; Bream JH; Taiwo B; Morris A
J Infect Dis; 2009 May; 199(9):1335-44. PubMed ID: 19301979
[TBL] [Abstract][Full Text] [Related]
8. Synthetic p55 tandem DNA vaccine against Pneumocystis carinii in rats.
Fan H; Guo JY; Ma SL; Zhang N; An CL
Microbiol Immunol; 2016 Jun; 60(6):397-406. PubMed ID: 27185490
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis colonization in immunocompetent and simian immunodeficiency virus-infected cynomolgus macaques.
Kling HM; Shipley TW; Patil S; Morris A; Norris KA
J Infect Dis; 2009 Jan; 199(1):89-96. PubMed ID: 19014344
[TBL] [Abstract][Full Text] [Related]
10. Current understanding of Pneumocystis immunology.
Kelly MN; Shellito JE
Future Microbiol; 2010 Jan; 5(1):43-65. PubMed ID: 20020829
[TBL] [Abstract][Full Text] [Related]
11. Immunization with Pneumocystis Cross-Reactive Antigen 1 (Pca1) Protects Mice against Pneumocystis Pneumonia and Generates Antibody to Pneumocystis jirovecii.
Tesini BL; Wright TW; Malone JE; Haidaris CG; Harber M; Sant AJ; Nayak JL; Gigliotti F
Infect Immun; 2017 Apr; 85(4):. PubMed ID: 28031260
[No Abstract] [Full Text] [Related]
12. Immunization with Pneumocystis carinii A12
Tong T; Wang Z; Xu Y; Shen J
BMC Immunol; 2021 Jun; 22(1):40. PubMed ID: 34174820
[TBL] [Abstract][Full Text] [Related]
13. Humoral immune responses to Pneumocystis jirovecii antigens in HIV-infected and uninfected young children with pneumocystis pneumonia.
Djawe K; Daly KR; Levin L; Zar HJ; Walzer PD
PLoS One; 2013; 8(12):e82783. PubMed ID: 24386119
[TBL] [Abstract][Full Text] [Related]
14. Ambient air pollution associated with suppressed serologic responses to Pneumocystis jirovecii in a prospective cohort of HIV-infected patients with Pneumocystis pneumonia.
Blount RJ; Djawe K; Daly KR; Jarlsberg LG; Fong S; Balmes J; Miller RF; Walzer PD; Huang L;
PLoS One; 2013; 8(11):e80795. PubMed ID: 24236202
[TBL] [Abstract][Full Text] [Related]
15. Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.
Blount RJ; Jarlsberg LG; Daly KR; Worodria W; Davis JL; Cattamanchi A; Djawe K; Andama A; Koch J; Walzer PD; Huang L;
PLoS One; 2012; 7(12):e51545. PubMed ID: 23284710
[TBL] [Abstract][Full Text] [Related]
16. Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients.
Blount RJ; Daly KR; Fong S; Chang E; Grieco K; Greene M; Stone S; Balmes J; Miller RF; Walzer PD; Huang L
PLoS One; 2017; 12(7):e0180212. PubMed ID: 28692651
[TBL] [Abstract][Full Text] [Related]
17. B cell and antibody responses in mice induced by a putative cell surface peptidase of Pneumocystis murina protect against experimental infection.
Ruan S; Cai Y; Ramsay AJ; Welsh DA; Norris K; Shellito JE
Vaccine; 2017 Jan; 35(4):672-679. PubMed ID: 28012778
[TBL] [Abstract][Full Text] [Related]
18. Immunization with recombinant Pneumocystis carinii p55 antigen provides partial protection against infection: characterization of epitope recognition associated with immunization.
Smulian AG; Sullivan DW; Theus SA
Microbes Infect; 2000 Feb; 2(2):127-36. PubMed ID: 10742685
[TBL] [Abstract][Full Text] [Related]
19. Active immunization against Pneumocystis carinii with a recombinant P. carinii antigen.
Wells J; Haidaris CG; Wright TW; Gigliotti F
Infect Immun; 2006 Apr; 74(4):2446-8. PubMed ID: 16552076
[TBL] [Abstract][Full Text] [Related]
20. Overcoming Hurdles to Development of a Vaccine against Pneumocystis jirovecii.
Garvy BA
Infect Immun; 2017 Apr; 85(4):. PubMed ID: 28115507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
